Suppression of JAK2/STAT3 Pathway by Notoginsenoside R1 Reduces Epithelial-Mesenchymal Transition in Non-small Cell Lung Cancer
Molecular Biotechnology · 2025
DOI: 10.1007/s12033-024-01136-3 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Biotechnology, 2025. Verfasst von Min Wan und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Laboratory, Wuhan Hospital of Traditional Chinese Medicine, Wuhan, 430014, China. Hauptthemen laut MEDLINE: Epithelial-Mesenchymal Transition, Janus Kinase 2, STAT3 Transcription Factor, Carcinoma, Non-Small-Cell Lung. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 41 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Laboratory, Wuhan Hospital of Traditional Chinese Medicine, Wuhan, 430014, China.
- Department of Oncology Hematology, Qianjiang Central Hospital, No.22 Zhanghua Road, Qianjiang, 433100, Hubei, China. zhaihaoqing@hotmail.com.
Zitieren
APA
Wan, M., Yu, H., & Zhai, H. (2025). Suppression of JAK2/STAT3 Pathway by Notoginsenoside R1 Reduces Epithelial-Mesenchymal Transition in Non-small Cell Lung Cancer. Molecular Biotechnology. https://doi.org/10.1007/s12033-024-01136-3
Vancouver
Wan M, Yu H, Zhai H. Suppression of JAK2/STAT3 Pathway by Notoginsenoside R1 Reduces Epithelial-Mesenchymal Transition in Non-small Cell Lung Cancer. Molecular Biotechnology. 2025. doi:10.1007/s12033-024-01136-3
BibTeX
@article{Wan2025,
author = {Wan, Min and Yu, Hong and Zhai, Haoqing},
title = {Suppression of JAK2/STAT3 Pathway by Notoginsenoside R1 Reduces Epithelial-Mesenchymal Transition in Non-small Cell Lung Cancer},
journal = {Molecular Biotechnology},
year = {2025},
doi = {10.1007/s12033-024-01136-3}
}
EUVIMED